Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 19, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 200,000 ordinary shares.
- Price Per Share: 1,489.9896 pence.
- Treasury Shares Held: 200,921,678 shares following the transaction.
- Shares in Issue: 5,785,925,665 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 17, 2006. The company executed the purchase of 200,000 shares on October 19, 2006, and intends to hold them in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 200,000 share repurchase based on the disclosed price of 1,489.9896 pence per share.
- Confirm the updated total number of shares in issue (5,785,925,665) against subsequent filings.
- Review the remaining authorization for share buybacks under the mandate granted on May 17, 2006.